Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
Authors:
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (1) , 72-78
Abstract
Objective To determine the most effective induction disease-modifying antirheumatic drug (DMARD) strategy in early rheumatoid arthritis (RA), second to compare one single dose of intramuscular glucocorticoids (GCs) with daily oral GCs during the induction phase. Methods The 3-month data of a single-blinded clinical trial in patients with recent-onset arthritis (tREACH) were used. Patients were included who had a high probability (>70%) of progressing to persistent arthritis, based on the prediction model of Visser. Patients were randomised into three induction therapy strategies: (A) combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with GCs intramuscularly; (B) combination therapy with an oral GC tapering scheme and (C) MTX with oral GCs similar to B. A total of 281 patients were randomly assigned to strategy (A) (n=91), (B) (n=93) or (C) (n=97). Results The Disease Activity Score (DAS) after 3 months was lower in patients receiving initial combination therapy than in those receiving MTX monotherapy (0.39 (0.67 to 0.11, 95% CI)). DAS did not differ between the different GC bridging treatments. After 3 months 50% fewer biological agents were prescribed in the combination therapy groups. Although the proportion of patients with medication adjustments differed significantly between the treatment arms, no differences were seen in these adjustments due to adverse events after stratification for drug. Conclusion Triple DMARD induction therapy is better than MTX monotherapy in early RA. Furthermore, no differences were seen in medication adjustments due to adverse events after stratification for drug. Intramuscular and oral GCs are equally effective as bridging treatments and both can be used.Keywords
This publication has 23 references indexed in Scilit:
- Similar effects of disease‐modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: Meta‐analysis of 70 randomized placebo‐controlled or drug‐controlled studies, including 112 comparisonsArthritis & Rheumatism, 2010
- Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six‐month, multicenter, randomized, double‐blind, controlled, phase IV trialArthritis & Rheumatism, 2007
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trialArthritis & Rheumatism, 2005
- Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?Arthritis & Rheumatism, 2005
- How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritisArthritis & Rheumatism, 2002
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- A self‐administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic researchArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Measurement of disability in Dutch rheumatoid arthritis patientsClinical Rheumatology, 1984